PDF icon Download PDF
Semin Liver Dis 2025; 45(01): 129-143
DOI: 10.1055/a-2542-9930
Review Article

Recompensation in Cirrhosis: Biomarkers and Strategies

Wagner Ramírez-Quesada   *
1   Barcelona Hepatic Hemodynamic Laboratory, Liver Unit, Hospital Clínic, Institut de Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Barcelona, Spain
2   Departament de Medicina i Ciències de la Salut, Fundació de Recerca Clínic Barcelona (FRCB-IDIBAPS), Health Care Provider of the European Reference Network on Rare Liver Disorders (ERN-RareLiver), Universitat de Barcelona, Barcelona, Spain
,
Edilmar Alvarado-Tapias   *   #
3   Centre for Biomedical Research in Liver and Digestive Diseases Network (CIBERehd), Instituto de Salud Carlos III, Madrid, Spain
4   Gastroenterology and Hepatology Department, Hospital Santa Creu i Sant Pau, Autonomus University of Barcelona, Barcelona, Spain
,
Sarah Shalaby
1   Barcelona Hepatic Hemodynamic Laboratory, Liver Unit, Hospital Clínic, Institut de Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Barcelona, Spain
2   Departament de Medicina i Ciències de la Salut, Fundació de Recerca Clínic Barcelona (FRCB-IDIBAPS), Health Care Provider of the European Reference Network on Rare Liver Disorders (ERN-RareLiver), Universitat de Barcelona, Barcelona, Spain
,
Virginia Hernández-Gea   #
1   Barcelona Hepatic Hemodynamic Laboratory, Liver Unit, Hospital Clínic, Institut de Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Barcelona, Spain
2   Departament de Medicina i Ciències de la Salut, Fundació de Recerca Clínic Barcelona (FRCB-IDIBAPS), Health Care Provider of the European Reference Network on Rare Liver Disorders (ERN-RareLiver), Universitat de Barcelona, Barcelona, Spain
3   Centre for Biomedical Research in Liver and Digestive Diseases Network (CIBERehd), Instituto de Salud Carlos III, Madrid, Spain
› Author Affiliations
Financial Support and Sponsorship This work was supported by FIS 23/00997, funded by “Instituto de Salud Carlos III” and co-funded by the European Union. From “CIBEREHD” funded by “Instituto de Salud Carlos III.”  From the “Commissioner for Universities and Research from the Department of Economy and Knowledge” of the “Generalitat de Catalunya” (AGAUR SGR2021 01115).  S.S. has a Rio Hortega Grant. The current contract is funded by “Instituto de Salud Carlos III” with charges to the European funds of the Recovery, Transformation, and Resilience Plan (Plan de Recuperación, Transformación y Resiliencia), with files code CM23/00068, according to the Resolution of the Instituto de Salud Carlos III, O.A., M.P. of December 2023, granting the Rio Hortega Contracts, and “Co-Financed by the European Union.” EAT has a “Juan Rodés Post-Doctoral Grant” funded by “Instituto de Salud Carlos III” with file code (JR20/00047), and the PI21/01995 funded by “Instituto de Salud Carlos III” and co-funded by the European Union. We also thank the CERCA Program/Generalitat de Catalunya.
› Further Information
   Permissions and Reprints


Preview

Abstract

The onset of decompensation in advanced chronic liver disease (ACLD) is a hallmark in natural history, with a poor prognosis and a significantly increased liver-related mortality. Etiological treatments for viral hepatitis or abstinence in cirrhosis due to alcohol abuse have demonstrated that some patients experience partial to complete clinical and analytical improvement, a stage termed “recompensation.” Although recompensation is primarily defined clinically based on treatable etiologies, it is still evolving for conditions like metabolic dysfunction-associated steatotic liver disease (MASLD). Despite the need for specific biomarkers in hepatic recompensation, no biomarkers have been thoroughly studied in this context. Biomarkers identified in compensated ACLD (cACLD) following etiological treatment might be explored for recompensation. Although the pathophysiology mechanisms underlying the hepatic recompensation remain unclear, understanding the mechanism involved in cirrhosis decompensation could help identify potential targets for recompensation. This review provides an update on the hepatic recompensation concept, examines the existing data on invasive and non-invasive biomarkers, mainly in cACLD after cure, that could be raised in recompensation, and explores future therapeutic targets for the hepatic recompensation process.

Keywords

cirrhosis - portal hypertension - recompensation - variceal bleeding - MASH

* Shared first author.


# Shared corresponding author.




Publication History

Article published online:
03 April 2025

© 2025. Thieme. All rights reserved.

Thieme Medical Publishers, Inc.
333 Seventh Avenue, 18th Floor, New York, NY 10001, USA

 

  • References

  • 1 Chung W, Jo C, Chung WJ, Kim DJ. Liver cirrhosis and cancer: comparison of mortality. Hepatol Int 2018; 12 (03) 269-276
    Search in Google Scholar
  • 2 Aravinthan AD, Barbas AS, Doyle AC. et al. Characteristics of liver transplant candidates delisted following recompensation and predictors of such delisting in alcohol-related liver disease: a case-control study. Transpl Int 2017; 30 (11) 1140-1149
    Search in Google Scholar
  • 3 Pose E, Torrents A, Reverter E. et al. A notable proportion of liver transplant candidates with alcohol-related cirrhosis can be delisted because of clinical improvement. J Hepatol 2021; 75 (02) 275-283
    Search in Google Scholar
  • 4 Hofer BS, Simbrunner B, Hartl L. et al. Hepatic recompensation according to Baveno VII criteria is linked to a significant survival benefit in decompensated alcohol-related cirrhosis. Liver Int 2023; 43 (10) 2220-2231
    Search in Google Scholar
  • 5 Gratacós-Ginès J, Pose E. Defining recompensation of alcohol-related liver disease: a step beyond decompensated cirrhosis. Liver Int 2023; 43 (10) 2060-2061
    Search in Google Scholar
  • 6 Yao FY, Terrault NA, Freise C, Maslow L, Bass NM. Lamivudine treatment is beneficial in patients with severely decompensated cirrhosis and actively replicating hepatitis B infection awaiting liver transplantation: a comparative study using a matched, untreated cohort. Hepatology 2001; 34 (02) 411-416
    Search in Google Scholar
  • 7 Wang Q, Zhao H, Deng Y. et al. Validation of Baveno VII criteria for recompensation in entecavir-treated patients with hepatitis B-related decompensated cirrhosis. J Hepatol 2022; 77 (06) 1564-1572
    Search in Google Scholar
  • 8 Hui VWK, Wong GLH, Wong VWS. et al. Baveno VII criteria for recompensation predict transplant-free survival in patients with hepatitis B-related decompensated cirrhosis. JHEP Rep Innov Hepatol 2023; 5 (09) 100814
    Search in Google Scholar
  • 9 Deng Y, Kang H, Xiang H. et al. Durability and on-treatment predictors of recompensation in entecavir-treated patients with hepatitis B and decompensated cirrhosis. JHEP Rep Innov Hepatol 2024; 6 (07) 101091
    Search in Google Scholar
  • 10 Perricone G, Duvoux C, Berenguer M. et al; European Liver and Intestine Transplant Association (ELITA). Delisting HCV-infected liver transplant candidates who improved after viral eradication: outcome 2 years after delisting. Liver Int 2018; 38 (12) 2170-2177
    Search in Google Scholar
  • 11 Bittermann T, Reddy KR. In the era of direct-acting antivirals, liver transplant delisting due to clinical improvement for hepatitis C remains infrequent. Clin Gastroenterol Hepatol 2021; 19 (11) 2389-2397.e2
    Search in Google Scholar
  • 12 Nabatchikova EA, Abdurakhmanov DT, Rozina TP, Nikulkina EN, Tanaschuk EL, Moiseev SV. Delisting and clinical outcomes of liver transplant candidates after hepatitis C virus eradication: a long-term single-center experience. Clin Res Hepatol Gastroenterol 2021; 45 (06) 101714
    Search in Google Scholar
  • 13 Xu X, Wang H, Zhao W, Wang Y, Wang J, Qin B. Recompensation factors for patients with decompensated cirrhosis: a multicentre retrospective case-control study. BMJ Open 2021; 11 (06) e043083
    Search in Google Scholar
  • 14 de Franchis R, Bosch J, Garcia-Tsao G, Reiberger T, Ripoll C. Baveno VII Faculty. Baveno VII—renewing consensus in portal hypertension. J Hepatol 2022; 76 (04) 959-974
    Search in Google Scholar
  • 15 Papatheodoridis GV, Hatzakis A, Cholongitas E. et al. Hepatitis C: the beginning of the end-key elements for successful European and national strategies to eliminate HCV in Europe. J Viral Hepat 2018; 25 (Suppl. 01) 6-17
    Search in Google Scholar
  • 16 Mandorfer M, Kozbial K, Schwabl P. et al. Sustained virologic response to interferon-free therapies ameliorates HCV-induced portal hypertension. J Hepatol 2016; 65 (04) 692-699
    Search in Google Scholar
  • 17 Lens S, Alvarado-Tapias E, Mariño Z. et al. Effects of all-oral anti-viral therapy on HVPG and systemic hemodynamics in patients with hepatitis C virus-associated cirrhosis. Gastroenterology 2017; 153 (05) 1273-1283.e1
    Search in Google Scholar
  • 18 Nahon P, Bourcier V, Layese R. et al; ANRS CO12 CirVir Group. Eradication of hepatitis C virus infection in patients with cirrhosis reduces risk of liver and non-liver complications. Gastroenterology 2017; 152 (01) 142-156.e2
    Search in Google Scholar
  • 19 Di Marco V, Calvaruso V, Ferraro D. et al. Effects of eradicating hepatitis C virus infection in patients with cirrhosis differ with stage of portal hypertension. Gastroenterology 2016; 151 (01) 130-139.e2
    Search in Google Scholar
  • 20 Persico M, Rosato V, Aglitti A. et al. Sustained virological response by direct antiviral agents in HCV leads to an early and significant improvement of liver fibrosis. Antivir Ther 2018; 23 (02) 129-138
    Search in Google Scholar
  • 21 Younossi ZM, Stepanova M, Racila A. et al. Long-term benefits of sustained virologic response for patient-reported outcomes in patients with chronic hepatitis C virus infection. Clin Gastroenterol Hepatol 2020; 18 (02) 468-476.e11
    Search in Google Scholar
  • 22 Yeh ML, Liang PC, Tsai PC. et al. Characteristics and survival outcomes of hepatocellular carcinoma developed after HCV SVR. Cancers (Basel) 2021; 13 (14) 3455
    Search in Google Scholar
  • 23 Mengshol JA, Golden-Mason L, Rosen HR. Mechanisms of disease: HCV-induced liver injury. Nat Clin Pract Gastroenterol Hepatol 2007; 4 (11) 622-634
    Search in Google Scholar
  • 24 El-Sherif O, Jiang ZG, Tapper EB. et al. Baseline factors associated with improvements in decompensated cirrhosis after direct-acting antiviral therapy for hepatitis C virus infection. Gastroenterology 2018; 154 (08) 2111-2121.e8
    Search in Google Scholar
  • 25 Krassenburg LAP, Maan R, Ramji A. et al. Clinical outcomes following DAA therapy in patients with HCV-related cirrhosis depend on disease severity. J Hepatol 2021; 74 (05) 1053-1063
    Search in Google Scholar
  • 26 Verna EC, Morelli G, Terrault NA. et al. DAA therapy and long-term hepatic function in advanced/decompensated cirrhosis: real-world experience from HCV-TARGET cohort. J Hepatol 2020; 73 (03) 540-548
    Search in Google Scholar
  • 27 Pascasio JM, Vinaixa C, Ferrer MT. et al. Clinical outcomes of patients undergoing antiviral therapy while awaiting liver transplantation. J Hepatol 2017; 67 (06) 1168-1176
    Search in Google Scholar
  • 28 Belli LS, Berenguer M, Cortesi PA. et al; European Liver and Intestine Association (ELITA). Delisting of liver transplant candidates with chronic hepatitis C after viral eradication: a European study. J Hepatol 2016; 65 (03) 524-531
    Search in Google Scholar
  • 29 Yuen MF, Chen DS, Dusheiko GM. et al. Hepatitis B virus infection. Nat Rev Dis Primers 2018; 4 (01) 18035
    Search in Google Scholar
  • 30 Marcellin P, Gane E, Buti M. et al. Regression of cirrhosis during treatment with tenofovir disoproxil fumarate for chronic hepatitis B: a 5-year open-label follow-up study. Lancet 2013; 381 (9865) 468-475
    Search in Google Scholar
  • 31 Lim YS, Chan HLY, Ahn SH. et al. Tenofovir alafenamide and tenofovir disoproxil fumarate reduce incidence of hepatocellular carcinoma in patients with chronic hepatitis B. JHEP Rep Innov Hepatol 2023; 5 (10) 100847
    Search in Google Scholar
  • 32 He Z, Wang B, Wu X. et al. Recompensation in treatment-naïve HBV-related decompensated cirrhosis: a 5-year multi-center observational study comparing patients with ascites and bleeding. Hepatol Int 2023; 17 (06) 1368-1377
    Search in Google Scholar
  • 33 Seitz HK, Bataller R, Cortez-Pinto H. et al. Alcoholic liver disease. Nat Rev Dis Primers 2018; 4 (01) 16
    Search in Google Scholar
  • 34 Parés A, Caballería J, Bruguera M, Torres M, Rodés J. Histological course of alcoholic hepatitis. Influence of abstinence, sex and extent of hepatic damage. J Hepatol 1986; 2 (01) 33-42
    Search in Google Scholar
  • 35 Tacke F, Horn P, Wai-Sun Wong V. et al; European Association for the Study of the Liver (EASL), European Association for the Study of Diabetes (EASD), European Association for the Study of Obesity (EASO). EASL-EASD-EASO Clinical Practice Guidelines on the management of metabolic dysfunction-associated steatotic liver disease (MASLD). J Hepatol 2024; 81 (03) 492-542
    Search in Google Scholar
  • 36 Estes C, Razavi H, Loomba R, Younossi Z, Sanyal AJ. Modeling the epidemic of nonalcoholic fatty liver disease demonstrates an exponential increase in burden of disease. Hepatology 2018; 67 (01) 123-133
    Search in Google Scholar
  • 37 Feng G, Valenti L, Wong VWS. et al. Recompensation in cirrhosis: unravelling the evolving natural history of nonalcoholic fatty liver disease. Nat Rev Gastroenterol Hepatol 2024; 21 (01) 46-56
    Search in Google Scholar
  • 38 Suárez M, Boqué N, Del Bas JM, Mayneris-Perxachs J, Arola L, Caimari A. Mediterranean diet and multi-ingredient-based interventions for the management of non-alcoholic fatty liver disease. Nutrients 2017; 9 (10) 1052
    Search in Google Scholar
  • 39 Kawaguchi T, Charlton M, Kawaguchi A. et al. Effects of mediterranean diet in patients with nonalcoholic fatty liver disease: a systematic review, meta-analysis, and meta-regression analysis of randomized controlled trials. Semin Liver Dis 2021; 41 (03) 225-234
    Search in Google Scholar
  • 40 Loomba R, Abdelmalek MF, Armstrong MJ. et al; NN9931–4492 investigators. Semaglutide 2·4 mg once weekly in patients with non-alcoholic steatohepatitis-related cirrhosis: a randomised, placebo-controlled phase 2 trial. Lancet Gastroenterol Hepatol 2023; 8 (06) 511-522
    Search in Google Scholar
  • 41 Harrison SA, Bedossa P, Guy CD. et al; MAESTRO-NASH Investigators. A phase 3, randomized, controlled trial of resmetirom in NASH with liver fibrosis. N Engl J Med 2024; 390 (06) 497-509
    Search in Google Scholar
  • 42 Bazerbachi F, Vargas EJ, Rizk M. et al. Intragastric balloon placement induces significant metabolic and histologic improvement in patients with nonalcoholic steatohepatitis. Clin Gastroenterol Hepatol 2021; 19 (01) 146-154.e4
    Search in Google Scholar
  • 43 Pedersen JS, Rygg MO, Serizawa RR. et al. Effects of Roux-en-Y gastric bypass and sleeve gastrectomy on non-alcoholic fatty liver disease: a 12-month follow-up study with paired liver biopsies. J Clin Med 2021; 10 (17) 3783
    Search in Google Scholar
  • 44 Paternostro R, Kwanten WJ, Hofer BS. et al; a study by the Baveno Cooperation: an EASL consortium. Hepatic venous pressure gradient predicts risk of hepatic decompensation and liver-related mortality in patients with MASLD. J Hepatol 2024; 81 (05) 827-836
    Search in Google Scholar
  • 45 Rinella ME, Neuschwander-Tetri BA, Siddiqui MS. et al. AASLD practice guidance on the clinical assessment and management of nonalcoholic fatty liver disease. Hepatology 2023; 77 (05) 1797-1835
    Search in Google Scholar
  • 46 Sanyal AJ, Anstee QM, Trauner M. et al. Cirrhosis regression is associated with improved clinical outcomes in patients with nonalcoholic steatohepatitis. Hepatology 2022; 75 (05) 1235-1246
    Search in Google Scholar
  • 47 Lavín-Alconero L, Fernández-Lanas T, Iruzubieta-Coz P. et al. Efficacy and safety of endoscopic sleeve gastroplasty versus laparoscopic sleeve gastrectomy in obese subjects with Non-Alcoholic SteatoHepatitis (NASH): study protocol for a randomized controlled trial (TESLA-NASH study). Trials 2021; 22 (01) 756
    Search in Google Scholar
  • 48 Leung KK, Deeb M, Hirschfield GM. Review article: pathophysiology and management of primary biliary cholangitis. Aliment Pharmacol Ther 2020; 52 (07) 1150-1164
    Search in Google Scholar
  • 49 Nevens F, Andreone P, Mazzella G. et al; POISE Study Group. A placebo-controlled trial of obeticholic acid in primary biliary cholangitis. N Engl J Med 2016; 375 (07) 631-643
    Search in Google Scholar
  • 50 Corpechot C, Chazouillères O, Rousseau A. et al. A placebo-controlled trial of bezafibrate in primary biliary cholangitis. N Engl J Med 2018; 378 (23) 2171-2181
    Search in Google Scholar
  • 51 Hirschfield GM, Bowlus CL, Mayo MJ. et al; RESPONSE Study Group. A phase 3 trial of seladelpar in primary biliary cholangitis. N Engl J Med 2024; 390 (09) 783-794
    Search in Google Scholar
  • 52 Kowdley KV, Bowlus CL, Levy C. et al; ELATIVE Study Investigators' Group, ELATIVE Study Investigators' Group. Efficacy and safety of elafibranor in primary biliary cholangitis. N Engl J Med 2024; 390 (09) 795-805
    Search in Google Scholar
  • 53 Levy C, Manns M, Hirschfield G. New treatment paradigms in primary biliary cholangitis. Clin Gastroenterol Hepatol 2023; 21 (08) 2076-2087
    Search in Google Scholar
  • 54 Hofer BS, Burghart L, Halilbasic E. et al. Evaluation of potential hepatic recompensation criteria in patients with PBC and decompensated cirrhosis. Aliment Pharmacol Ther 2024; 59 (08) 962-972
    Search in Google Scholar
  • 55 FDA-NIH Biomarker Working Group. Response biomarker. In: BEST (Biomarkers, EndpointS, and Other Tools) Resource. Food and Drug Administration (US): National Institutes of Health; 2021
    Search in Google Scholar
  • 56 Hammel P, Couvelard A, O'Toole D. et al. Regression of liver fibrosis after biliary drainage in patients with chronic pancreatitis and stenosis of the common bile duct. N Engl J Med 2001; 344 (06) 418-423
    Search in Google Scholar
  • 57 Arthur MJ. Reversibility of liver fibrosis and cirrhosis following treatment for hepatitis C. Gastroenterology 2002; 122 (05) 1525-1528
    Search in Google Scholar
  • 58 Cheng CH, Chu CY, Chen HL. et al. Direct-acting antiviral therapy of chronic hepatitis C improves liver fibrosis, assessed by histological examination and laboratory markers. J Formos Med Assoc 2021; 120 (05) 1259-1268
    Search in Google Scholar
  • 59 Kweon YO, Goodman ZD, Dienstag JL. et al. Decreasing fibrogenesis: an immunohistochemical study of paired liver biopsies following lamivudine therapy for chronic hepatitis B. J Hepatol 2001; 35 (06) 749-755
    Search in Google Scholar
  • 60 Dixon JB, Bhathal PS, Hughes NR, O'Brien PE. Nonalcoholic fatty liver disease: improvement in liver histological analysis with weight loss. Hepatology 2004; 39 (06) 1647-1654
    Search in Google Scholar
  • 61 Czaja AJ, Carpenter HA. Decreased fibrosis during corticosteroid therapy of autoimmune hepatitis. J Hepatol 2004; 40 (04) 646-652
    Search in Google Scholar
  • 62 Lassailly G, Caiazzo R, Ntandja-Wandji LC. et al. Bariatric surgery provides long-term resolution of nonalcoholic steatohepatitis and regression of fibrosis. Gastroenterology 2020; 159 (04) 1290-1301.e5
    Search in Google Scholar
  • 63 Mendoza YP, Tsouka S, Semmler G. et al. Metabolic phenotyping of patients with advanced chronic liver disease for better characterization of cirrhosis regression. J Hepatol 2024; 81 (06) 983-994
    Search in Google Scholar
  • 64 Wanless IR, Nakashima E, Sherman M. Regression of human cirrhosis. Morphologic features and the genesis of incomplete septal cirrhosis. Arch Pathol Lab Med 2000; 124 (11) 1599-1607
    Search in Google Scholar
  • 65 de Franchis R. Baveno VI Faculty. Expanding consensus in portal hypertension: report of the Baveno VI Consensus Workshop: stratifying risk and individualizing care for portal hypertension. J Hepatol 2015; 63 (03) 743-752
    Search in Google Scholar
  • 66 Bosch J, Abraldes JG, Berzigotti A, García-Pagan JC. The clinical use of HVPG measurements in chronic liver disease. Nat Rev Gastroenterol Hepatol 2009; 6 (10) 573-582
    Search in Google Scholar
  • 67 Reiberger T, Schwabl P, Trauner M, Peck-Radosavljevic M, Mandorfer M. Measurement of the hepatic venous pressure gradient and transjugular liver biopsy. J Vis Exp 2020; (160) e58819
    Search in Google Scholar
  • 68 Lens S, Baiges A, Alvarado-Tapias E. et al. Clinical outcome and hemodynamic changes following HCV eradication with oral antiviral therapy in patients with clinically significant portal hypertension. J Hepatol 2020; 73 (06) 1415-1424
    Search in Google Scholar
  • 69 Mandorfer M, Kozbial K, Schwabl P. et al. Changes in hepatic venous pressure gradient predict hepatic decompensation in patients who achieved sustained virologic response to interferon-free therapy. Hepatology 2020; 71 (03) 1023-1036
    Search in Google Scholar
  • 70 Semmler G, Alonso López S, Pons M. et al; cACLD-SVR Study Group. Post-treatment LSM rather than change during treatment predicts decompensation in patients with cACLD after HCV cure. J Hepatol 2024; 81 (01) 76-83
    Search in Google Scholar
  • 71 Vorobioff J, Groszmann RJ, Picabea E. et al. Prognostic value of hepatic venous pressure gradient measurements in alcoholic cirrhosis: a 10-year prospective study. Gastroenterology 1996; 111 (03) 701-709
    Search in Google Scholar
  • 72 Hofer BS, Simbrunner B, Hartl L. et al. Alcohol abstinence improves prognosis across all stages of portal hypertension in alcohol-related cirrhosis. Clin Gastroenterol Hepatol 2023; 21 (09) 2308-2317.e7
    Search in Google Scholar
  • 73 Olivas P, Soler-Perromat A, Tellez L. et al. Persistent varices in cured patients: understanding the role of hepatic venous pressure gradient. JHEP Rep Innov Hepatol 2024; 6 (10) 101170
    Search in Google Scholar
  • 74 Premkumar M, Dhiman RK, Duseja A. et al. Recompensation of chronic hepatitis C-related decompensated cirrhosis following direct-acting antiviral therapy: prospective cohort study from an HCV elimination program. Gastroenterology 2024; 167 (07) 1429-1445
    Search in Google Scholar
  • 75 Wen S, Ruan J, Shen J. et al. Development and validation of a nomogram to predict recompensation in HBV-related cirrhosis with ascites as the single first decompensating event. Scand J Gastroenterol 2023; 58 (08) 915-922
    Search in Google Scholar
  • 76 Berzigotti A, Seijo S, Arena U. et al. Elastography, spleen size, and platelet count identify portal hypertension in patients with compensated cirrhosis. Gastroenterology 2013; 144 (01) 102-111.e1
    Search in Google Scholar
  • 77 Semmler G, Lens S, Meyer EL. et al; A study by the Baveno Cooperation: an EASL consortium. Non-invasive tests for clinically significant portal hypertension after HCV cure. J Hepatol 2022; 77 (06) 1573-1585
    Search in Google Scholar
  • 78 Prakash S, Kinder K, Brown KE. Spleen size change after hepatitis C treatment: a simple parameter to predict clinical outcomes. J Investig Med 2023; 71 (06) 603-612
    Search in Google Scholar
  • 79 Hsu SJ, Tsai MH, Chang CC. et al. Extrahepatic angiogenesis hinders recovery of portal hypertension and collaterals in rats with cirrhosis resolution. Clin Sci (Lond) 2018; 132 (06) 669-683
    Search in Google Scholar
  • 80 Saks K, Jensen KK, McLouth J. et al. Influence of spontaneous splenorenal shunts on clinical outcomes in decompensated cirrhosis and after liver transplantation. Hepatol Commun 2018; 2 (04) 437-444
    Search in Google Scholar
  • 81 De Carlis L, Del Favero E, Rondinara G. et al. The role of spontaneous portosystemic shunts in the course of orthotopic liver transplantation. Transpl Int 1992; 5 (01) 9-14
    Search in Google Scholar
  • 82 D'Ambrosio R, Aghemo A, Rumi MG. et al. The course of esophageal varices in patients with hepatitis C cirrhosis responding to interferon/ribavirin therapy. Antivir Ther 2011; 16 (05) 677-684
    Search in Google Scholar
  • 83 Takakusagi S, Saito N, Ueno T. et al. Changes of esophageal varices in hepatitis C patients after achievement of a sustained viral response by direct-acting antivirals. DEN Open 2021; 2 (01) e11
    Search in Google Scholar
  • 84 Puigvehí M, Londoño MC, Torras X. et al. Impact of sustained virological response with DAAs on gastroesophageal varices and Baveno criteria in HCV-cirrhotic patients. J Gastroenterol 2020; 55 (02) 205-216
    Search in Google Scholar
  • 85 D'Ambrosio R, Degasperi E, Anolli MP. et al. Incidence of liver- and non-liver-related outcomes in patients with HCV-cirrhosis after SVR. J Hepatol 2022; 76 (02) 302-310
    Search in Google Scholar
  • 86 Castera L, Pinzani M, Bosch J. Non invasive evaluation of portal hypertension using transient elastography. J Hepatol 2012; 56 (03) 696-703
    Search in Google Scholar
  • 87 Dajti E, Ravaioli F, Marasco G. et al. A combined Baveno VII and spleen stiffness algorithm to improve the noninvasive diagnosis of clinically significant portal hypertension in patients with compensated advanced chronic liver disease. Am J Gastroenterol 2022; 117 (11) 1825-1833
    Search in Google Scholar
  • 88 Dajti E, Ravaioli F, Zykus R. et al; Spleen Stiffness—IPD-MA Study Group. Accuracy of spleen stiffness measurement for the diagnosis of clinically significant portal hypertension in patients with compensated advanced chronic liver disease: a systematic review and individual patient data meta-analysis. Lancet Gastroenterol Hepatol 2023; 8 (09) 816-828
    Search in Google Scholar
  • 89 Semmler G, López SA, Pons M. et al. Long-term outcome and risk stratification in compensated advanced chronic liver disease after HCV-cure. Hepatology 2025; 81 (02) 609-624
    Search in Google Scholar
  • 90 Vizzutti F, Arena U, Romanelli RG. et al. Liver stiffness measurement predicts severe portal hypertension in patients with HCV-related cirrhosis. Hepatology 2007; 45 (05) 1290-1297
    Search in Google Scholar
  • 91 Thiele M, Villesen IF, Niu L. et al; MicrobLiver Consortium, GALAXY Consortium. Opportunities and barriers in omics-based biomarker discovery for steatotic liver diseases. J Hepatol 2024; 81 (02) 345-359
    Search in Google Scholar
  • 92 Schlevogt B, Deterding K, Port K. et al. Interferon-free cure of chronic hepatitis C is associated with weight gain during long-term follow-up. Z Gastroenterol 2017; 55 (09) 848-856
    Search in Google Scholar
  • 93 Schlevogt B, Boeker KHW, Mauss S. et al. Weight gain after interferon-free treatment of chronic hepatitis C—results from the German hepatitis C-registry (DHC-R). Biomedicines 2021; 9 (10) 1495
    Search in Google Scholar
  • 94 Do A, Esserman DA, Krishnan S. et al. Excess weight gain after cure of hepatitis C infection with direct-acting antivirals. J Gen Intern Med 2020; 35 (07) 2025-2034
    Search in Google Scholar
  • 95 Negro F. Facts and fictions of HCV and comorbidities: steatosis, diabetes mellitus, and cardiovascular diseases. J Hepatol 2014; 61 (01) S69-S78
    Search in Google Scholar
  • 96 Giard JM, Dodge JL, Terrault NA. Superior wait-list outcomes in patients with alcohol-associated liver disease compared with other indications for liver transplantation. Liver Transpl 2019; 25 (09) 1310-1320
    Search in Google Scholar
  • 97 Adami GF, Carbone F, Montecucco F, Camerini G, Cordera R. Adipose tissue composition in obesity and after bariatric surgery. Obes Surg 2019; 29 (09) 3030-3038
    Search in Google Scholar
  • 98 Pournaras DJ, Glicksman C, Vincent RP. et al. The role of bile after Roux-en-Y gastric bypass in promoting weight loss and improving glycaemic control. Endocrinology 2012; 153 (08) 3613-3619
    Search in Google Scholar
  • 99 Feng G, Han Y, Yang W. et al. Recompensation in MASLD-related cirrhosis via metabolic bariatric surgery. Trends Endocrinol Metab 2025; 36 (02) 118-132
    Search in Google Scholar
  • 100 Hafeez S, Ahmed MH. Bariatric surgery as potential treatment for nonalcoholic fatty liver disease: a future treatment by choice or by chance?. J Obes 2013; 2013 (01) 839275
    Search in Google Scholar
  • 101 Costa D, Simbrunner B, Jachs M. et al. Systemic inflammation increases across distinct stages of advanced chronic liver disease and correlates with decompensation and mortality. J Hepatol 2021; 74 (04) 819-828
    Search in Google Scholar
  • 102 Angeli P, Bernardi M, Villanueva C. et al; European Association for the Study of the Liver. EASL Clinical Practice Guidelines for the management of patients with decompensated cirrhosis. J Hepatol 2018; 69 (02) 406-460
    Search in Google Scholar
  • 103 Gao L, Li MB, Li JY, Liu Y, Ren C, Feng DP. Impressive recompensation in transjugular intrahepatic portosystemic shunt-treated individuals with complications of decompensated cirrhosis based on Baveno VII criteria. World J Gastroenterol 2023; 29 (38) 5383-5394
    Search in Google Scholar
  • 104 Sánchez J, González S, Poyatos P. et al. Recompensation after TIPS reduces the incidence of hepatocellular carcinoma and increases survival in patients with cirrhosis. Liver Int 2024; 44 (11) 3072-3082
    Search in Google Scholar
  • 105 Bosch J, Gracia-Sancho J, Abraldes JG. Cirrhosis as new indication for statins. Gut 2020; 69 (05) 953-962
    Search in Google Scholar
  • 106 Abraldes JG, Rodríguez-Vilarrupla A, Graupera M. et al. Simvastatin treatment improves liver sinusoidal endothelial dysfunction in CCl4 cirrhotic rats. J Hepatol 2007; 46 (06) 1040-1046
    Search in Google Scholar
  • 107 Abraldes JG, Albillos A, Bañares R. et al. Simvastatin lowers portal pressure in patients with cirrhosis and portal hypertension: a randomized controlled trial. Gastroenterology 2009; 136 (05) 1651-1658
    Search in Google Scholar
  • 108 Zafra C, Abraldes JG, Turnes J. et al. Simvastatin enhances hepatic nitric oxide production and decreases the hepatic vascular tone in patients with cirrhosis. Gastroenterology 2004; 126 (03) 749-755
    Search in Google Scholar
  • 109 Trebicka J, Hennenberg M, Laleman W. et al. Atorvastatin lowers portal pressure in cirrhotic rats by inhibition of RhoA/Rho-kinase and activation of endothelial nitric oxide synthase. Hepatology 2007; 46 (01) 242-253
    Search in Google Scholar
  • 110 Boyer-Diaz Z, Aristu-Zabalza P, Andrés-Rozas M. et al. Pan-PPAR agonist lanifibranor improves portal hypertension and hepatic fibrosis in experimental advanced chronic liver disease. J Hepatol 2021; 74 (05) 1188-1199
    Search in Google Scholar
  • 111 Newsome PN, Buchholtz K, Cusi K. et al; NN9931–4296 Investigators. A placebo-controlled trial of subcutaneous semaglutide in nonalcoholic steatohepatitis. N Engl J Med 2021; 384 (12) 1113-1124
    Search in Google Scholar
  • 112 Knudsen LB, Lau J. The discovery and development of liraglutide and semaglutide. Front Endocrinol (Lausanne) 2019; 10: 155
    Search in Google Scholar
  • 113 Brusilovskaya K, Königshofer P, Lampach D. et al. Soluble guanylyl cyclase stimulation and phosphodiesterase-5 inhibition improve portal hypertension and reduce liver fibrosis in bile duct-ligated rats. United European Gastroenterol J 2020; 8 (10) 1174-1185
    Search in Google Scholar
  • 114 Eizayaga FX, Aguejouf O, Belon P, Doutremepuich C. Platelet aggregation in portal hypertension and its modification by ultra-low doses of aspirin. Pathophysiol Haemost Thromb 2005; 34 (01) 29-34
    Search in Google Scholar
  • 115 Schwabl P, Hambruch E, Seeland BA. et al. The FXR agonist PX20606 ameliorates portal hypertension by targeting vascular remodelling and sinusoidal dysfunction. J Hepatol 2017; 66 (04) 724-733
    Search in Google Scholar
  • 116 Mookerjee R, Rosselli M, Pieri G. et al. O15 Effects of the FXR agonist obeticholic acid on hepatic venous pressure gradient (HVPG) in alcoholic cirrhosis: a proof of concept phase 2a study. J Hepatol 2014; 60 (01) S7-S8
    Search in Google Scholar
  • 117 Vilaseca M, García-Calderó H, Lafoz E. et al. The anticoagulant rivaroxaban lowers portal hypertension in cirrhotic rats mainly by deactivating hepatic stellate cells. Hepatology 2017; 65 (06) 2031-2044
    Search in Google Scholar
  • 118 Sanchez AP, Turon F, Martinez J. et al. Rivaroxaban improves survival and decompensation in cirrhotic patients with moderate liver dysfunction. Double-blind, placebo-controlled trial. J Hepatol 2023; 78 (01) S2-S3
    Search in Google Scholar
  • 119 Villa E, Cammà C, Marietta M. et al. Enoxaparin prevents portal vein thrombosis and liver decompensation in patients with advanced cirrhosis. Gastroenterology 2012; 143 (05) 1253-1260.e4
    Search in Google Scholar
  • 120 Tacke F. Targeting hepatic macrophages to treat liver diseases. J Hepatol 2017; 66 (06) 1300-1312
    Search in Google Scholar
  • 121 Anstee QM, Neuschwander-Tetri BA, Wai-Sun Wong V. et al. Cenicriviroc lacked efficacy to treat liver fibrosis in nonalcoholic steatohepatitis: AURORA phase III randomized study. Clin Gastroenterol Hepatol 2024; 22 (01) 124-134.e1
    Search in Google Scholar
  • 122 Ratziu V, Sanyal A, Harrison SA. et al. Cenicriviroc treatment for adults with nonalcoholic steatohepatitis and fibrosis: final analysis of the phase 2b CENTAUR study. Hepatology 2020; 72 (03) 892-905
    Search in Google Scholar
  • 123 Liu S, Wu J, Chen P, Mohammed SAD, Zhang J, Liu S. TAK-242 ameliorates hepatic fibrosis by regulating the liver-gut axis. BioMed Res Int 2022; 2022 (01) 4949148
    Search in Google Scholar
  • 124 Puengel T, De Vos S, Hundertmark J. et al. The medium-chain fatty acid receptor GPR84 mediates myeloid cell infiltration promoting steatohepatitis and fibrosis. J Clin Med 2020; 9 (04) 1140
    Search in Google Scholar
  • 125 Linton SD. Caspase inhibitors: a pharmaceutical industry perspective. Curr Top Med Chem 2005; 5 (16) 1697-1717
    Search in Google Scholar
  • 126 Ferguson D, Finck BN. Emerging therapeutic approaches for the treatment of NAFLD and type 2 diabetes mellitus. Nat Rev Endocrinol 2021; 17 (08) 484-495
    Search in Google Scholar
  • 127 Bataller R, Arab JP, Shah VH. Alcohol-associated hepatitis. N Engl J Med 2022; 387 (26) 2436-2448
    Search in Google Scholar
  • 128 Reiberger T, Angermayr B, Schwabl P. et al. Sorafenib attenuates the portal hypertensive syndrome in partial portal vein ligated rats. J Hepatol 2009; 51 (05) 865-873
    Search in Google Scholar
  • 129 Pinter M, Sieghart W, Reiberger T, Rohr-Udilova N, Ferlitsch A, Peck-Radosavljevic M. The effects of sorafenib on the portal hypertensive syndrome in patients with liver cirrhosis and hepatocellular carcinoma—a pilot study. Aliment Pharmacol Ther 2012; 35 (01) 83-91
    Search in Google Scholar
  • 130 Yang L, Kwon J, Popov Y. et al. Vascular endothelial growth factor promotes fibrosis resolution and repair in mice. Gastroenterology 2014; 146 (05) 1339-50.e1
    Search in Google Scholar